To Be or Not to Be: Amiodarone as Both Savior and Foe-A Therapeutic Paradox in Atrial Fibrillation Management and Ventricular Arrhythmia Associated with Amiodarone-Induced Thyrotoxicosis.

Monika Amielan, Małgorzata Zalewska-Adamiec, Hanna Bachórzewska-Gajewska, Sławomir Dobrzycki

Abstract readCase Reports

In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Monika AmielanDepartment of Invasive Cardiology, Internal Medicine with CICU and Laboratory of Hemodynamics, University Hospital in Bialystok, 15-089 Bialystok, Poland.

Małgorzata Zalewska-AdamiecDepartment of Invasive Cardiology, Internal Medicine with CICU and Laboratory of Hemodynamics, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-2466-4093

Hanna Bachórzewska-GajewskaDepartment of Invasive Cardiology, Internal Medicine with CICU and Laboratory of Hemodynamics, University Hospital in Bialystok, 15-089 Bialystok, Poland.

Sławomir DobrzyckiDepartment of Invasive Cardiology, Internal Medicine with CICU and Laboratory of Hemodynamics, Medical University of Bialystok, 15-089 Bialystok, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amiodarone-induced thyrotoxicosis (AIT) is a serious thyroid dysfunction that represents a significant complication of pharmacological therapy in cardiology patients. The development of AIT can substantially complicate the management of cardiac arrhythmias, posing a major clinical challenge. We present the case of a patient in whom amiodarone was initially effective in the treatment of atrial fibrillation but subsequently led to type II amiodarone-induced thyrotoxicosis and exacerbation of the atrial arrhythmia. This case highlights the need for regular monitoring of patients treated with amiodarone, the challenges of managing arrhythmias in the setting of AIT, and the importance of close collaboration between cardiologists and endocrinologists in the diagnosis and treatment of AIT.

Indexed as

amiodaroneamiodarone-induced thyrotoxicosisatrial fibrillationthyrotoxicosis

Identifiers

PMID42514204

DOI10.3390/life16071134

PMCPMC13412609

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.